Leerink Partners Sticks to Its Buy Rating for Vericel (VCEL)
BTIG Maintains Vericel(VCEL.US) With Buy Rating, Raises Target Price to $66
Vericel Is Maintained at Buy by Canaccord Genuity
Vericel Analyst Ratings
CCORF Maintains Vericel(VCEL.US) With Buy Rating, Maintains Target Price $60
CCORF Maintains Vericel(VCEL.US) With Buy Rating, Raises Target Price to $60
Truist Financial Maintains Vericel(VCEL.US) With Buy Rating, Announces Target Price $61
TD Cowen Maintains Vericel(VCEL.US) With Buy Rating, Maintains Target Price $60
H.C. Wainwright Maintains Vericel(VCEL.US) With Buy Rating, Maintains Target Price $60
Ladenburg Thalmann Maintains Vericel(VCEL.US) With Buy Rating, Raises Target Price to $56
A Quick Look at Today's Ratings for Vericel(VCEL.US), With a Forecast Between $56 to $60
Vericel Analyst Ratings
CCORF Maintains Vericel(VCEL.US) With Buy Rating, Maintains Target Price $57
BTIG Maintains Vericel(VCEL.US) With Buy Rating, Maintains Target Price $55
TD Cowen Maintains Vericel(VCEL.US) With Buy Rating, Raises Target Price to $60
Buy Rating on Vericel: Expanding Market Reach With FDA-Approved MACI Arthro Platform
Analysts Offer Insights on Healthcare Companies: CureVac (CVAC), Vericel (VCEL) and Twist Bioscience (TWST)
TD Cowen Maintains Vericel(VCEL.US) With Buy Rating, Maintains Target Price $55
TD Cowen Keeps Their Buy Rating on Vericel (VCEL)
Vericel Analyst Ratings
No Data
No Data